GS-5885, a NS5A inhibitor developed by Gilead for hepatitis C, has shown promising results in a recent study. Twenty five patients with genotype 1 chronic hepatitis C were given a combination of GS-5885, ribavirin, and sofosbuvir for 12 weeks. Four weeks after finishing therapy, all patients showed an undetectable level of hepatitis C infection. GS-5885 works by stopping the hepatitis C virus from replicating. What medications are currently approved for hepatitis C infection?
For more information, please read the article from Reuters.com.
“Image courtesy of [dream designs]/FreeDigitalPhotos.net“